TWST — Twist Bioscience Corporation stock price and chart

TWST

$111.60-2.29%

as of close, Nov 13, 2026

☾ AH $111.60 -2.29%

Twist Bioscience CorporationStock · HealthcareRussell 2000 · 0.2% of IWMNasdaq Composite · 0.02% of ONEQUS Stock Market · 0.008% of VTIRussell 3000 · 0.008% of IWV

PeersTXGTEMGMABIBRXSPYQQQ

Share this page

Head-to-head:Compare with TXG or any ticker →

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Nov 6, 2018

Volume14.2M

EEEEEEEEEEEEEEEEEEEEEE

20192020202120222023202420252026

0.020.040.060.080.0100.0120.0140.0160.0180.0200.0010.0M20.0M30.0M$111.60

2026-11-13

Price$111.60

MA20$130.34

MA50$81.88

Vol14.2M

Data provided bySource: Twelve Data

What would $1,000 invested in TWST be worth today? →

TWST returns: By year · By month · By week · Trailing

Key stats#

Data provided bySource: Twelve Data

Price data

Price: $111.60
YTD price return: +251.83%
YTD total return: +251.83%
Market cap: 7B2018-12 646.9M2026-11 7B+980.8% over the window
Enterprise value: 6.9B
Shares outstanding: 62.7M2018-09 3.2M2026-06 62.7M+1855.9% over the window
52W low: $23.30
52W high: $219.71
From 52W high: -49.21%
From 52W low: +378.97%
52W range: 45%$23.30–$220

Volume

Rel volume: 0.71×
30D volume: 2.9M
30D $ vol: 424.9M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1M0 insider-days of buying (no priced lot) and 6 of selling ($1.6M) in the last 30 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$1.6M
Insider net 3M0 insider-days of buying (no priced lot) and 34 of selling ($99.9M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$99.9M
Insider net 1Y0 insider-days of buying (no priced lot) and 117 of selling ($147.6M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$147.6M

Form 4 transactions by trade date, as filed; latest on file 2026-11-03.

Fundamentals

Sales (ttm): 431.8M2017-09 10.8M2026-06 431.8M+3910.4% over the window
Sales/share: $6.892018-09 $7.932026-06 $6.89-13.2% over the window
EPS (ttm): -$2.232020-09 -$3.572026-06 -$2.23-37.6% over the window
FCF (ttm): -93.1M2017-09 -57.9M2026-06 -93.1M+60.8% over the window
FCF/share: -$1.492018-09 -$21.792026-06 -$1.49-93.2% over the window
Book value/share: $7.112018-03 -$51.692026-06 $7.11-113.8% over the window
Net margin: -31.66%2017-09 -550.8%2026-06 -31.7%-94.3% over the window
ROE: -30.67%2018-12 -55.5%2026-06 -30.7%-44.7% over the window
ROA: -20.33%2018-09 -61.5%2026-06 -20.3%-67.0% over the window
Debt / equity: 0.03×2018-12 0.052026-06 0.03-28.5% over the window
Current ratio: 2.672018-09 5.162026-06 2.67-48.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +19.21%2025-06-30 → 2026-06-30362.3M → 431.8M (+19.2% total)+22.39%2023-06-30 → 2026-06-30235.5M → 431.8M (+83.4% total)+27.77%2021-06-30 → 2026-06-30126.8M → 431.8M (+240.5% total)n/a
Shares: +3.89%2025-06-30 → 2026-06-3060.4M → 62.7M (+3.9% total)+2.99%2023-06-30 → 2026-06-3057.4M → 62.7M (+9.3% total)+4.93%2021-06-30 → 2026-06-3049.3M → 62.7M (+27.2% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +14.74%2025-06-30 → 2026-06-30$6.00 → $6.89 (+14.7% total)+18.84%2023-06-30 → 2026-06-30$4.10 → $6.89 (+67.8% total)+21.77%2021-06-30 → 2026-06-30$2.57 → $6.89 (+167.7% total)n/a
Book value/share: -10.28%2025-06-30 → 2026-06-30$7.92 → $7.11 (-10.3% total)-14.71%2023-06-30 → 2026-06-30$11.46 → $7.11 (-38.0% total)-10.51%2021-06-30 → 2026-06-30$12.38 → $7.11 (-42.6% total)n/a
Price: +273.58%2025-11-13 → 2026-11-13$29.90 → $111.60 (+273.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+86.27%2023-11-13 → 2026-11-13$17.26 → $111.60 (+546.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-0.85%2021-11-12 → 2026-11-13$116.48 → $111.60 (-4.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +273.58%2025-11-13 → 2026-11-13$29.90 → $111.60 (+273.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+86.27%2023-11-13 → 2026-11-13$17.26 → $111.60 (+546.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-0.85%2021-11-12 → 2026-11-13$116.48 → $111.60 (-4.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -50.1×2018-12 -8.412026-11 -51.14+508.2% over the window
Fwd P/E: -330.3×
P/S (ttm)Market cap ÷ TTM revenue.: 16.2×2018-12 19.842026-11 16.19-18.4% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 15.7×2018-12 4.672026-11 15.69+236.1% over the window
EV/Sales (ttm): 16.1×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -1.33%2018-09 -10.8%2026-06 -1.4%-86.6% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 62.7M ÷ 60.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -3.89%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-3.89%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -3.89%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($7B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2019-09 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($7B). Same caveat as the cash buyback yield.: 0.00%2019-09 0.0%2026-06 0.0%

Vs own 10Y history

P/S: 61st
P/B: 95th

Bar = where today’s multiple sits in TWST’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data

-2.29%

-7.61%

-26.25%

-10.93%

YTD

+251.83%

+273.24%

-4.19%

-2.29%

-7.61%

-26.25%

-10.93%

YTD

+251.83%

+273.24%

-4.19%

Fundamentals#

Revenue

5Y CAGR +33.1%5Y CAGR +33.1%YoY +23.2%

$431.8M TTM$118.4M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m

−$145M TTM−$36.3M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

EPS (diluted)

5Y n/m5Y n/mYoY n/m

−$2.23 TTM−$0.56 Q3 '26

FY20FY21FY22FY23FY24FY25TTM

Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m

−$93.1M TTM−$8.6M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$53.1M, capex −$40.1M

Q3 2026: operating cash flow $1.1M, capex −$9.8M

Shares (diluted)

5Y +52.6%5Y +52.6%YoY +2.0%

61.4M TTM62.4M Q3 '26

FY20FY21FY22FY23FY24FY25TTM

Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m

−$136.7M TTM−$35.1M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Full TWST financials →

About Twist Bioscience#

Data provided bySource: Twelve Data

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.

South San Francisco, CA·979 employees·Biotechnology·twistbioscience.com·As of Oct 30, 2026

Recent filings#

Nov 12Earnings · Earnings release — EPS −$0.32 vs −$0.43 est. (+25.6%) 6.8%
Nov 3Insider sale · Leproust Emily M. (Chief Executive Officer · Director) sold 20,302 shares for $2.5M on 5 days since Aug 3
Nov 3Insider sale · Finn Patrick John (President and COO) sold 39,696 shares for $6.5M on 6 days since Jul 23
Nov 3Insider sale · Green Paula (SVP of Human Resources) sold 14,789 shares for $2.5M on 6 days since Aug 3
Nov 3Insider sale · Cho Dennis (See Remarks) sold 13,891 shares for $2.3M on 6 days since Aug 3

All filings and insider trades →

ETFs holding TWST#

17 of the 193 ETFs ChartRow carries live hold TWST. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

Fund	Name	Filed weight
ARKK	ARK Innovation ETF	3.3%
XBI	SPDR S&P Biotech ETF	1.4%
IBB	iShares Biotechnology ETF	0.5%
IWO	iShares Russell 2000 Growth ETF	0.4%
VTWO	Vanguard Russell 2000 ETF	0.3%
IWM	iShares Russell 2000 ETF	0.2%
VBK	Vanguard Small-Cap Growth ETF	0.2%
VHT	Vanguard Health Care ETF	0.1%

Data provided bySource: Twelve Data

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+23.75%	+1.14%
JNJ	Johnson & Johnson	+14.94%	+0.79%
ABBV	AbbVie Inc.	+7.53%	+0.20%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+7.86%	+0.58%
MRK	Merck & Co. Inc.	+4.07%	+0.55%
NVS	Novartis AG	+12.70%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+5.61%	+0.11%
AMGN	Amgen Inc.	+12.80%	-0.30%

Head-to-head:Compare with TXG or any ticker →

TWST — Twist Bioscience Corporation price, chart and key statistics

Key stats#

Price data

Volume

Insider trading

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price returntotal return · as of 2026-11-13#

Fundamentals#

Revenue

Operating income

EPS (diluted)

Free cash flow

Shares (diluted)

Net income

About Twist Bioscience#

Recent filings#

ETFs holding TWST#

Related Healthcare#